SKAN Group (0SKN) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of SKAN Group £10.46, price £67.80, upside -84.6%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
57‑month range £40.40 – £88.80 · fair‑value band £7.85 – £12.48 · the £67.80 price screens above the £10.46 fair value. Dashed = 300-day average. As of Sep 24, 2026.
SKAN Group AG, together with its subsidiaries, provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. It operates in two segments, Equipment and Solutions; and Services and Consumables.
Show more
SKAN Group AG, together with its subsidiaries, provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. It operates in two segments, Equipment and Solutions; and Services and Consumables. The company offers accessories, biological indicators, digital ventures, isolators, cleanroom, laminar flow, particle counter, personal protective equipment, safety workbench, transfer systems, and fume cupboard. It also provides digital solutions, lifecycle support, laboratory services, and SKAN labs. The company was formerly known as BV Holding AG and changed its name to SKAN Group AG in October 2021. SKAN Group AG was founded in 1968 and is headquartered in Allschwil, Switzerland.
Stock analysis
SKAN Group (0SKN) currently trades at £67.80, while our model-based Fair Value estimate is £10.46, 84.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of £39.48 per share, and 0 of the 23 models we run sit above the £67.80 price.
Bear case: the Asset-Based group reads lowest at £1.20, and 23 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: £7.85 (bear) to £12.48 (bull), the price of £67.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
SKAN Group reported revenue of £13.8M in FY2020 versus £17.4M in FY2016, a compound −5.5%/yr. Reported net income was £12.8M in FY2020, compounding −5.4%/yr from FY2016.
Key figures
Market cap £1.6B · P/S ratio 4.71 · Dividend yield 0.3% · Net margin 92.5% · Return on equity 10.6% · Return on assets (EBIT) 16.2% · Operating margin 15.3% · Revenue growth (YoY) +0.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −85%, 0SKN screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (£1.20 to £39.48). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear £7.85Fair Value £10.46Bull £12.48
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−26.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
’16
’17
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
92.8% (2016) → 92.5% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SKAN Group Fair Value". https://www.fairvalue-calculator.com/stock/0SKN
Frequently asked questions
Is SKAN Group (0SKN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of £10.46 versus a price of £67.80, about −85% upside (overvalued).
What is the fair value of 0SKN?
Our model-based fair value for SKAN Group is £10.46 (as of Sep 24, 2026), built from audited fundamentals. The current price: £67.80.
What is the quality score of 0SKN?
SKAN Group has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SKAN Group (0SKN)?
Our model-based price target is the fair value of £10.46 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario £7.85, optimistic scenario £12.48. It is a calculation from audited fundamentals, not an analyst target.
What is the SKAN Group stock forecast for 2026?
Our models put fair value at £10.46, about −85% upside versus a price of £67.80 (overvalued). Cautious scenario £7.85, optimistic scenario £12.48. The calculation is refreshed regularly with new filings.
Does SKAN Group pay a dividend?
SKAN Group currently shows a dividend yield of about 0.32% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of SKAN Group (0SKN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SKAN Group it is £10.46 per share (as of Sep 24, 2026), against a price of £67.80. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is SKAN Group stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0SKN trades above its calculated fair value: price £67.80, fair value £10.46, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0SKN?
No. The price is what the market pays today (£67.80); the fair value is what the company's own numbers justify (£10.46). For SKAN Group the two are £57.34 per share apart. That gap is exactly why we show both numbers side by side.
How much is SKAN Group worth?
The market values SKAN Group at about £1.6B (market capitalisation, as of Sep 24, 2026). Per share that is £67.80; our models calculate a fair value of £10.46 per share.
What do the bullish and bearish scenarios say about 0SKN?
Our models span a range for SKAN Group: cautious scenario £7.85, base £10.46, optimistic £12.48 per share (as of Sep 24, 2026, price £67.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0SKN from its 52-week high?
SKAN Group trades at £67.80, about 4% below its 52-week high of £70.30 and 68% above the low of £40.40 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of £10.46 is for.
Which stocks are comparable to SKAN Group?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SKAN Group stock attractive at the current price?
The data as of Sep 24, 2026: price £67.80, calculated fair value £10.46 (−85%), Quality Score 60/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0SKN calculated?
We run SKAN Group through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £10.46, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. SKAN Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SKAN Group (0SKN)?
The closing price on Oct 2, 2026 was £67.80. Our model-based fair value is £10.46, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SKAN Group right now?
The price sits above even our optimistic bull case (£12.48). The favourable scenario is already priced in. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of SKAN Group
How large is the market capitalisation of SKAN Group (0SKN)?
The market capitalisation of SKAN Group is £1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SKAN Group (0SKN)?
The price-to-sales ratio of SKAN Group is 4.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of SKAN Group (0SKN)?
The dividend yield of SKAN Group is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SKAN Group (0SKN)?
The net margin of SKAN Group is 92.5% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SKAN Group (0SKN)?
The return on equity (ROE) of SKAN Group is 10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SKAN Group (0SKN)?
On an EBIT basis the return on assets of SKAN Group is 16.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SKAN Group (0SKN)?
The operating margin of SKAN Group is 15.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SKAN Group (0SKN)?
Revenue at SKAN Group is growing +0.6% versus a year earlier (3y avg −4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SKAN Group (0SKN)?
Earnings per share at SKAN Group are growing +0.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
